Introduction
The trans-membrane glycoprotein CD4 is a major component of the immunological synapse, which participates in the optimal activation of T lymphocytes during the immune response [1] . We previously demonstrated that the anti-CD4 rIgG 1 13B8.2 antibody inhibits T lymphocyte proliferation and IL-2 secretion [2] , leading to growth arrest, ADCC and CDC of T lymphoma cells [3] , through signals that prevent NF-κB nuclear translocation. Specifically, the rIgG 1 13B8.2 antibody induces CD4 accumulation in GM1 † -positive membrane rafts and reorganization of signalling proteins involved in TCR-mediated immune response [4] , through recruitment of CD3, Lyn, p56 Lck and LAT and exclusion of ZAP-70, SLP-76, PLC1 and Vav-1 from membrane rafts of Jurkat T cells [4] . Moreover, 13B8.2 increases ceramide release through acid sphingomyelinase activation and decreases phosphatidylserine synthesis without modifying the cholesterol content of GM1-positive membrane rafts [5] .
However, we did not identify the link between the proximal modulation of the lipid-protein rheostat in membrane rafts and the downstream inhibition of NF-κB observed following treatment with 13B8.2.
T cells activation by APC is triggered through co-stimulation of the TCR/CD3
complex and the CD28 receptor [6] . This co-stimulation (known as CD3/CD28 activation)
induces transduction pathways that lead to the activation of tyrosine kinases (such as and adapter proteins (like SLP-76 and Vav-1) that in turn induce the activity of multiple transcription factors, including NF-κB, leading to T cell activation and proliferation. The scaffolding molecule Carma1, a member of the MAGUK family of proteins [7] , is at the crossroads of the CD3-and CD28-induced pathways leading to NF-κB activation. Carma1 is a lipid raft-associated regulator of TCR-induced NF-B activation, located in the inner leaflet of the membrane [8] . Upon CD3/CD28-mediated PKCθ phosphorylation [9, 10] , Carma1 is inserm-00588709, version 1 -26 Apr 2011
mouse IgG (Sigma-Aldrich) at 37°C for 4 h, as previously described [8] .
Brij 98 raft isolation
After washing in 160 mM PBS (pH 7.4), cells were lysed at 37°C in 1% Brij 98 detergent diluted in TNE buffer (25 mM Tris-HCl, pH 7.5; 150 mM NaCl; 5 mM EDTA and 1 mg/ml enzyme inhibitors) (complete EDTA-free mixture of anti-proteases; Roche) for 30 min. Cell lysates were mixed with an equal volume of 80% sucrose in TNE, overlaid with 6.5 ml of 30% and 3.5 ml of 5% sucrose in TNE, and then centrifuged at 200,000 g for 20 h [4, 5] . Twelve 1-ml fractions were collected on ice starting from the top of the gradient and numbered from 1 to 12. The protein content of each fraction was quantified with the micro Bradford Protein Assay kit (Pierce) [4, 5] . GM1 and CD71 expression were used to discriminate between rafts and non-rafts fractions (see below).
Dot blot analysis of GM1-enriched membrane rafts
Nitrocellulose membranes (Hybond ECL; Amersham) were spotted with 2 µg of proteins from each gradient fraction. Membranes were blocked with 5% semi-skimmed milk in PBS containing 0.1% Tween 20 (PBS-T) at room temperature for 1 h and then incubated with peroxidase-conjugated cholera toxin B subunit (1:1000) at room temperature for 1 h (GM1 detection) or with an anti-CD71 rabbit antibody (1:1000) (Santa Cruz Biotech.) at 37°C for 1 h (CD71 detection), followed by a secondary peroxidase-conjugated anti-rabbit antibody (1:3000). After washing in PBS-T, binding was revealed with the ECL Western Blotting
Detection Kit (Amersham) [4] . Neither the experiments performed for this paper, nor the dot inserm-00588709, version 1 -26 Apr 2011
blots/western blots we previously published [4, 5] showed GM1 and CD71 reactivity in fractions 1-3 of the membrane raft gradient.
SDS-polyacrylamide gel (SDS-PAGE) electrophoresis and western blotting
Forty µg of each gradient fraction were separated on 12% SDS-PAGE under reducing conditions and electrophoretically transferred to Immobilon P membranes (Bio-Rad).
Membranes were blocked with 5% semi-skimmed milk in PBS-T at 37°C for 1 h. After washing in PBS-T, membranes were incubated with anti-Carma1, -Bcl10 and -MALT1 acquisition was performed on five to ten different microscopic fields in the same slide from three to five independent experiments for each condition. For a given cell, the ratio of colocalization (Intensity Correlation Quotient or ICQ) was measured using the method described by Li and co-workers [15] and ImageJ software (http://rsbweb.nih.gov/ij/) and JACoP plugin [16] . This intensity correlation coefficient-based method processed image stacks by measuring pixel intensities to calculate the ICQ [17] . Briefly, when two proteins are part of the same complex their staining intensities will vary in synchrony (i.e., dependent staining); whereas if they are in different complexes they will exhibit asynchronous staining (i.e., segregated staining) [15] . The ICQ provides an overall index of whether the staining intensities are associated in a random, dependent or segregated manner [15] . ICQ values inserm-00588709, version 1 -26 Apr 2011 fluctuate from 0.5 (dependent staining, indicating co-localization) to -0.5 (segregated staining, demonstrating exclusion).
Statistical analysis
Results, when appropriate, were expressed as mean ± SD and were the average of at whereas CD71 (non-raft fractions) was expressed in fractions 10-12. This distribution of raft and non-raft fractions was not influenced by the different treatments (Fig.1) . Then, the localization of Carma1, Bcl10 and MALT1 in GM1 + raft and CD71 + non-raft fractions was investigated by western blotting (Fig.2) . In the absence of CD3/CD28 activation, Carma1, Bcl10 and MALT1 were mainly located in the non-raft fraction 12 in untreated cells (Fig.2, left panel) and in cells incubated with 13B8.2 or rituximab for 15 min or 240 min (4 h) (Fig.2, left panel). Pre-activation with CD3/CD28 antibodies induced accumulation of Carma1, Bcl10 and MALT1 in raft fractions 4-6 (Fig.2, right panel) . Conversely, when pre-activation was followed by a 15-min treatment with 13B8.2 ( Fig.2, right panel) , but not with rituximab ( Fig.2, right panel) , these adapter proteins were partially segregated from GM1 + rafts and localized in fractions 8 and 9 and in the CD71 + non-raft fraction 12. This reorganization of the Carma1-Bcl10-MALT1 complex in fraction 12 was complete in CD3/CD28 activated Jurkat T cells that were treated with rIgG 1 13B8.2 for 240 min (Fig.2, right panel) .
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These results indicate that 13B8.2 segregates the Carma1-Bcl10-MALT1 complex, which is involved in the pathway which leads to NF-κB activation [10] (Fig.3) .
GM1/Carma1 co-patching is abrogated by 13B8.2 treatment of CD3/CD28 activated

Jurkat T cells
The effects of 13B8.2 on Carma1 partitioning in raft/non-raft fractions were then investigated using confocal microscopy. Carma1 co-localization with GM1 was assessed in Jurkat T cells that had been left without treatment, pre-activated with CD3/CD28 antibodies, or incubated with 13B8.2 or rituximab for 24 h after, or not, CD3/CD28 activation. GM1 and Carma1 co-patched in CD3/CD28 activated cells (Fig. 4A ), but not in untreated cells or treated with 13B8.2 or rituximab) had ICQ values around 0.25 ( Fig. 4B ), in agreement with the absence of GM1 and Carma1 co-patching (Fig. 4A) . Conversely, the ICQ of CD3/CD28-activated cells was significantly increased to 0.45, confirming the co-localization of GM1 and Carma1 (Fig. 4A) . This value decreased significantly to 0.27 in CD3/CD28-activated cells treated with 13B8.2, whereas it remained unchanged (ICQ=0.45) in CD3/CD28-activated cells incubated with rituximab. These results indicate that GM1/Carma1 co-patching in CD3/CD28-activated Jurkat T cells is blocked by treatment with 13B8.2.
The Carma1-Bcl10-MALT1 complex is disassembled by 13B8.2 treatment
To determine the consequences of 13B8.2 treatment on the Carma1-Bcl10-MALT1
complex after its reorganization outside GM1 + membrane rafts, Carma1, Bcl10 and MALT1
co-patching was assessed by confocal microscopy in Jurkat T cells that were or not activated with CD3/CD28 antibodies and treated or not with 13B8.2 or rituximab for 24 h. No copatching was observed, in untreated (medium) cells or after incubation with 13B8.2 ( Fig. 5A and 5B), whereas in CD3/CD28 activated cells Carma1 co-localized with both Bcl10 ( 
Discussion
In this study we show that treatment of CD3/CD28-activated Jurkat T cells with the anti-CD4 rIgG 1 13B8.2 antibody excludes Carma1-Bcl10-MALT1 proteins from GM1 + membrane rafts and that this dissociation occurs concomitantly with the reduction of NF-κB activation. These results suggest that 13B8.2 inhibits NF-κB signalling through the raft exclusion and consequent dissociation of the Carma1-Bcl10-MALT1 complex. We previously demonstrated that 13B8.2 induces acid sphingomyelinase activation and membrane ceramide release [5] together with CD4/ZAP-70 reorganization in membrane rafts [4] . Such events modulate the lipid-protein rheostat and might participate in the exclusion of the Carma1-Bcl10-MALT1 complex from membrane rafts.
Upon antigen-induced stimulation of the Carma1-Bcl10-MALT1 complex, NF-B activation widely depends on Carma1 phosphorylation. PKCθ-triggered phosphorylation of Carma1 occurs at Serine 564 and 657 [18, 19] and contributes to Carma1 activation and assembly of the Carma1-Bcl10-MALT1 complex. A recent study, however, highlighted that a third PKC target site, Serine 649, triggers Carma1 down-regulation [20] , but the PKC family member that phosphorylates this residue has not been yet identified. Ceramide also regulates negatively NF-κB activation through inhibition of PKCθ [21] . Based on this information we hypothesize that 13B8.2 could induce dissociation of the Carma1-Bcl10-MALT1 complex through ceramide release, which in turn might act as a PKCθ inhibitor, thus promoting Carma1 down-regulation by phosphorylation of Serine 649.
Deregulation of the Carma1-Bcl10-MALT1 complex plays a role in various diseases [22] [23] [24] [25] [26] . Carma1 is a possible target gene of the 7p22 amplification, which had been identified in aggressive adult T-cell leukaemia [26] , as increased Carma1 transcription was observed. It also is over-expressed in angioimmunoblastic T-cell lymphoma and peripheral Tinserm-00588709, version 1 -26 Apr 2011
cell lymphoma [22] and is involved in the development of allergic airway inflammation [27] .
Bcl10 and MALT1 are over-expressed in MALT lymphomas due to the recurrent chromosomal translocations t(1;14)(p22;q32), t(11;18)(q21;q21) and t(14;18)(q32;q21) [23, 24, 28] . In all these cases, cells are 'supersensitized' to an antigen-induced signal leading to higher proliferation through NF-B excessive activation.
Since the NF-B pathway plays a pivotal role in promoting cell cycle progression, inhibiting apoptosis or regulating inflammation, NF-κB inhibitors could be of great interest in cancer therapy [29] . The first therapeutic attempts to target NF-κB upstream regulators involved proteasome (PS-341, MG132), IKK (NSAID, thalidomide) or antioxidant (glutathione) inhibitors. Bortezomib, a proteasome inhibitor, was approved for multiple myeloma treatment [30] and has been assessed alone for the treatment of cutaneous T-cell lymphoma [31] , or in combination with chemotherapy in aggressive T-cell leukaemia [32] .
Then, research focused on NF-κB RNA interference [33] , microRNA therapy [34] or blockage of NF-κB transcriptional activity [35] . However, most of these inhibitors lack specificity. Another class of upstream NF-κB inhibitors, which targets IKK (such as BMS-345541, SPC-839 or PS-1145 inhibitors) [36, 37] , are in development and show more specificity. Based on the results of this paper, we hypothesize that indirect pharmacologic inhibition of the Carma1-Bcl10-MALT1 signalosome by antibodies could provide new ways to block the NF-κB pathway in a more tissue specific manner, which could contribute to the chemosensitization of lymphomas. 
